| Parameters . | Age of P1 . | . | Age of P2 . | . | Age of P3 . | . | Age of P4 . | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 9 yr . | 17 yr . | 26 yr . | 30 yr . | 2.5 yr . | 5 yr . | 2.8 yr . | 8 yr . | ||||
| Diagnosis | CVID dx | HL dx | Genetic dx | Genetic dx | HL dx | Genetic dx | HL dx | Genetic dx | |||
| IgG, mg/dl | 389↓ (600–1,500) | 439↓a (600–1,500) | 843a (600–1,500) | 1,080 (600–1,500) | 315↓ (640–2,010) | 323↓a (640–2,010) | 462↓ (640–2,010) | 403↓ (764–2,134) | |||
| IgA, mg/dl | 76↓ (80–380) | <10↓ (80–380) | 67↓ (80–380) | 262 (80–380) | 6.7↓ (44–244) | <10↓ (50–266) | 27 (26–296) | 26↓ (70–303) | |||
| IgM, mg/dl | 48↓ (50–370) | <20↓ (50–370) | 16↓ (50–370) | 56 (50–370) | 18↓ (52–297) | <19↓ (51–373) | 52↓ (71–235) | 36↓ (69–387) | |||
| IgE, IU/ml | 3 (0–10) | 2 (0–10) | 3 (0–10) | 4 (0–10) | NA | NA | NA | NA | |||
| Antidiphtheria IgG, IU/ml | <0.01↓b (>0.01) | NA | 0.2a (>0.01) | ≤0.006↓c (>0.01) | NA | NA | NA | NA | |||
| Antitetanus IgG, IU/ml | <0.01↓b (>0.05) | NA | 1.04a (>0.05) | 0.03↓c (>0.05) | NA | NA | NA | NA | |||
| Antirubella IgG | NA | NA | NA | NA | NA | NA | Positive | NA | |||
| Anti-CMV IgG | NA | NA | Positivea | Positive | Positive | NA | Negative | NA | |||
| Anti-EBV VCA IgG | NA | NA | Positivea | Positive | Positive | NA | Positive | NA | |||
| Parameters . | Age of P1 . | . | Age of P2 . | . | Age of P3 . | . | Age of P4 . | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 9 yr . | 17 yr . | 26 yr . | 30 yr . | 2.5 yr . | 5 yr . | 2.8 yr . | 8 yr . | ||||
| Diagnosis | CVID dx | HL dx | Genetic dx | Genetic dx | HL dx | Genetic dx | HL dx | Genetic dx | |||
| IgG, mg/dl | 389↓ (600–1,500) | 439↓a (600–1,500) | 843a (600–1,500) | 1,080 (600–1,500) | 315↓ (640–2,010) | 323↓a (640–2,010) | 462↓ (640–2,010) | 403↓ (764–2,134) | |||
| IgA, mg/dl | 76↓ (80–380) | <10↓ (80–380) | 67↓ (80–380) | 262 (80–380) | 6.7↓ (44–244) | <10↓ (50–266) | 27 (26–296) | 26↓ (70–303) | |||
| IgM, mg/dl | 48↓ (50–370) | <20↓ (50–370) | 16↓ (50–370) | 56 (50–370) | 18↓ (52–297) | <19↓ (51–373) | 52↓ (71–235) | 36↓ (69–387) | |||
| IgE, IU/ml | 3 (0–10) | 2 (0–10) | 3 (0–10) | 4 (0–10) | NA | NA | NA | NA | |||
| Antidiphtheria IgG, IU/ml | <0.01↓b (>0.01) | NA | 0.2a (>0.01) | ≤0.006↓c (>0.01) | NA | NA | NA | NA | |||
| Antitetanus IgG, IU/ml | <0.01↓b (>0.05) | NA | 1.04a (>0.05) | 0.03↓c (>0.05) | NA | NA | NA | NA | |||
| Antirubella IgG | NA | NA | NA | NA | NA | NA | Positive | NA | |||
| Anti-CMV IgG | NA | NA | Positivea | Positive | Positive | NA | Negative | NA | |||
| Anti-EBV VCA IgG | NA | NA | Positivea | Positive | Positive | NA | Positive | NA | |||
Numbers in parentheses indicate reference range. CVID, common variable immune deficiency; Dx, diagnosis; NA, not available.
After commencing IVIG therapy.
Vaccinated with diphtheria, pertussis, tetanus triple vaccine at age 6 yr.
Vaccinated with tetanus-diphtheria adult booster vaccine at age 25 yr.